Verona Pharma plc
VRNA
Rangering i aksjer
#2195
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aksjekurs
$106.91
Sist synkronisert: 2025-10-07
Markedsverdi
$9.09B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Kategori
Healthcare
Aksjeprishistorikk for Verona Pharma plc (VRNA)
Høyeste sluttskurs: $106.85 den 2025-10-01
Laveste sluttskurs: $13.50 den 2017-04-01
Laveste sluttskurs: $13.50 den 2017-04-01
Aksjeprishistorikk for Verona Pharma plc fra 2017 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2025 | 154.19% |
| 2024 | 157.60% |
| 2023 | -2.67% |
| 2022 | 215.71% |
| 2021 | -30.29% |
| 2020 | 68.43% |
| 2019 | -55.34% |
| 2018 | -13.21% |
| 2017 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
